Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone food effect study in mCRPC
NCT01424930Phase 2Completed
- Sponsor
- Janssen Ortho
- Start
- Oct 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Ortho. Primary endpoint: Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication. Started Oct 2011; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01424930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01424930.